Company Filing History:
3 out of 5 
3 out of 281 
Years Active: 2021-2024
Title: Shigeki Mukoubata: Innovator in Anti-VEGF Antibody Development
Introduction
Shigeki Mukoubata is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of high-affinity antibodies. With a total of 3 patents, Mukoubata's work focuses on advancing medical treatments through innovative antibody design.
Latest Patents
Mukoubata's latest patents include the "High-affinity anti-VEGF antibody KLHa505." This invention aims to provide an antibody with significantly high affinity for vascular endothelial growth factor (VEGF) compared to prior art. The monoclonal antibody binds to VEGF with a dissociation constant of 1×10 mol/L or less. Another patent titled "High-affinity anti-VEGF antibody" shares a similar objective, emphasizing the importance of high-affinity binding in therapeutic applications.
Career Highlights
Throughout his career, Mukoubata has worked with prominent companies in the medical research field. He has been associated with Order-Made Medical Research Inc. and Santen Pharmaceutical Co., Ltd. His work in these organizations has contributed to the advancement of medical technologies and therapeutic solutions.
Collaborations
Mukoubata has collaborated with esteemed colleagues, including Yasufumi Murakami and Hirotada Akiyama. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.
Conclusion
Shigeki Mukoubata's contributions to the field of biotechnology, particularly in the development of high-affinity anti-VEGF antibodies, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and therapies.